Cefepime Dosing for Elderly Diabetic Patient with Foot Ulcer and Impaired Renal Function
For this patient with an eGFR of 25-30 mL/min (CrCl approximately 25-30 mL/min), cefepime should be dosed at 1 g every 24 hours as an intravenous infusion.
Dosing Algorithm Based on Renal Function
The FDA-approved dosing for cefepime requires adjustment based on creatinine clearance 1. For this patient:
- eGFR 25-30 mL/min: The standard recommendation is 1 g every 24 hours for moderate-to-severe infections
- If treating severe infection or targeting less susceptible organisms (MIC ≥4 mg/L), consider 2 g every 24 hours with close monitoring
Renal Function-Based Dosing Table:
- CrCl >60 mL/min: 2 g every 8-12 hours (standard dosing)
- CrCl 30-60 mL/min: 2 g every 12-24 hours (depending on severity)
- CrCl <30 mL/min: 1-2 g every 24 hours
- Hemodialysis: 1 g after each dialysis session
Critical Safety Considerations
This patient is at extremely high risk for cefepime-induced neurotoxicity given the combination of:
- Elderly age
- Severe renal impairment (eGFR 25-30 mL/min)
- Diabetes (independent risk factor)
Neurotoxicity Risk Factors:
The most significant predictor of cefepime-induced neurotoxicity is eGFR <30 mL/min/1.73 m² (odds ratio 10.06) 2. Other contributing factors present in this patient include advanced age, diabetes, and potential CNS vulnerability 3, 4, 2.
Monitor closely for: confusion, myoclonus, seizures, altered mental status, or muscle jerks. These symptoms may be subtle and mistaken for other causes 4. If any neurological symptoms develop, immediately check cefepime levels and consider discontinuation.
Target Trough Concentrations:
- Intermittent infusion: Keep trough <20 mg/L to minimize neurotoxicity risk 2
- For efficacy: Maintain free drug concentration >MIC for ≥60% of dosing interval 5
Pharmacokinetic Rationale
In patients with CrCl 25-30 mL/min, cefepime half-life extends dramatically from ~2 hours to 13-19 hours 6. The drug is 85% renally eliminated 1, making dose reduction essential. Studies demonstrate that:
- Standard dosing in renal impairment leads to drug accumulation and trough concentrations of 20-30 mg/L, associated with neurotoxicity 4
- Patients with CrCl <30 mL/min require dosing every 24 hours to prevent accumulation 7, 6
- Even with appropriate dose adjustment, 10% of patients with renal impairment develop neurotoxicity 4
Monitoring Requirements
Essential monitoring for this patient:
- Renal function: Check serum creatinine at least every 2-3 days during therapy 8
- Neurological status: Daily assessment for confusion, myoclonus, or seizure activity
- Clinical response: Evaluate foot ulcer healing, fever curve, inflammatory markers
- Consider therapeutic drug monitoring (TDM): Particularly if clinical response is inadequate or neurological symptoms emerge 4, 2
Additional Considerations for Diabetic Foot Infection
While treating the infection, ensure comprehensive foot care management 9, 10, 11:
- Assess for peripheral artery disease (check ankle-brachial index, pedal pulses)
- Evaluate for osteomyelitis if ulcer probes to bone
- Ensure appropriate wound care and off-loading
- Consider vascular imaging if healing is inadequate after 6 weeks
The patient's diabetes management requires optimization during acute infection, as hyperglycemia impairs wound healing 8. Monitor glucose closely and adjust diabetes medications for renal function.
Alternative Dosing Strategy
If targeting highly resistant organisms or if clinical response is suboptimal with 1 g every 24 hours, consider extended infusion: 2 g over 3 hours every 24 hours 7. This maintains drug concentrations above MIC for a greater percentage of the dosing interval while minimizing peak concentrations that contribute to neurotoxicity 3, 12.
Do not use standard doses (2 g every 8-12 hours) in this patient—this will result in dangerous drug accumulation and high risk of seizures and encephalopathy 1, 4, 2.